Review: Relationship between Erythropoietin Administration and Alterations of Renin-Angiotensin-Aldosterone

Abstract

The effect of erythropoietin (EPO) administration on the responsiveness of the renin-angiotensin-aldosterone system (RAAS) has not been established. Because patients with chronic kidney disease (CKD) require EPO for their management as CKD progresses, it is important to ascertain whether EPO treatment alters the RAAS. If EPO administration stimulates renin-angiotensin or aldosterone (ALDO) this intervention would mediate cardiovascular and renal injury, and consequently promote cardiovascular events and/or exacerbate the progression of renal disease.We reviewed the available publications investigating the effects of EPO on the RAAS. In CKD patients following EPO administration plasma renin activity (PRA) was unchanged in all three and ALDO was not altered in the two studies in which it was determined. In end-stage renal disease (ESRD) patients undergoing dialysis following EPO administration, four studies reported a decrease in PRA levels whereas the remaining nine disclosed no change in PRA levels.The changes in ALDO levels after EPO administration in ESRD patients were discrepant with two studies reporting an increase, two reporting a decrease and the remaining three disclosing no change.

Keywords

Erythropoietin Renin-angiotensin Aldosterone Chronic kidney disease End-stage renal disease

Get full access to this article

View all access options for this article.

References

Eggena P. , Willsey P. , Jamgotchian N. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991 ;261(5PT1):E642-6.

Brier M. , Bunke M. , Lathon P. Erythropoietin-induced antinatriuresis mediated by angiotensin II in perfused kidneys. J Am Soc Nephrol 1993 ;3:1583-90.

Nowicki M. , Kokot F. , Wiecek A. Influence of the renin-angiotensin system stimulation on erythropoietin production in patients with various forms of arterial hypertension. Nephron 1993;65:527-32.

Donnelly S. , Miller J. Losartan may modulate erythropoietin production. JRAAS 2001;2:255-60.

Epstein M. Aldosterone as a mediator of progressive kidney disease: pathogenetic and clinical implications. Am J Kidney Dis 2004 ;37:677-88.

Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001;19:829-42.

Lebel M. , Kingma I. , Grose JH et al. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998;9:97-104.

Portoles J. , Torralbo A. , Martin P. et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997 ;29:541-8.

Arik N. , Demirkan F. , Erbas B. Acute effect of erythropoietin on plasma renin activity and aldosterone levels in end-stage renal disease. Nephron 1992;60:111.

10.

Abraham PA , Opsahl JA , Rachael KM et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990;10:128-36.

11.

Okura Y. , Oshima T. , Yasunobu Y. et al. Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients. Hypertens Res Clin Exp 1996;19:91-5.

12.

Vlahakos DV , Balodimos C. , Papachristopoulos V. et al. Renin-angiotensin system stimulates erythropoietin secretion in chronic hemodialysis patients . Clin Nephrol 1995;43:53-9.

13.

Sasagawa I. , Nakada T. , Hashimoto T. et al. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. Int Urol Nephrol 1994;26:237-43.

14.

Selcuk Y. , San A. , Sahin M. et al. Effects of treatment with recombinant human erythropoietin on hemodynamic functions and vasoactive hormones in renal anemia. Tr J Med Sci 1994;22:271-5.

15.

Yeksan M. , Tamer N. , Turk S. et al. Hemodynamic changes with recombinant human erythropoietin therapy in uremic hemodialyzed patients. Tr J of Med Sci 1994;20:173-8.

16.

Yaqoob M. , Bell GM , Ahmad R. et al. Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop. Nephrol Dial Transplant 1992;7:125-8.

17.

Ono K. , Hisasue Y. The rate in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 1992;37:23-7.

18.

Jandeleit K. , Ehmer B. , Heintz B. et al. Hormonal and electrolyte changes under regular therapy with recombinant human erythropoietin in hemodialysis patients . Contrib Nephrol 1991;91:57-60.

19.

Kokot F. , Wiecek A. , Grzeszczak W. et al. Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients . Miner Electrolyte Metab 1990;16:25-9.

20.

Hori K. , Onoyama K. , Iseki K. et al. Hemodynamic and volume changes by recombinant human erythropoietin in the treatment of anemic hemodialysis patients. Clin Nephrol 1990;33:293-8.

21.

Steffen HM , Brunner R. , Müller R. et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin . Contrib Nephrol 1989;76:292-8.

22.

Verbeelen D. , Bossuyt A. , Smitz J. et al. Hemodynamics of patients with renal failure treated with recombinant human erythropoietin . Clin Nephrol 1989;13:6-11.

23.

Epstein M. Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift. NephSAP 2004;3:285-95.

24.

Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspective . Nephrol Dial Transplant 2003 ;18:1984-92.

25.

Silverberg D. , Wexler D. , Blum M. et al. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004;13:163-70.